SEPSIS & COVID-19 10th International Congress - Sepsis-Update 2021 DSG
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
FINAL PROGRAM
10th International Congress
SEPSIS &
COVID-19
PREFACE 4
GENERAL INFORMATION 6
ENDORSEMENTS 8
SCHEDULE AT A GLANCE 10
PROGRAM 16
Wednesday 17
Thursday 24
Friday 30
SPEAKERS & CHAIRS 36
COMPANIES & EXHIBITORS 46
Imprint
Deutsche Sepsis-Gesellschaft e.V.
Am Klinikum 1 • 07747 Jena, Germany
Tel.: +49 3641 939 66 87
Design: © Lindgrün GmbH | 2021
www.lindgruen-gmbh.com
WELCOME TO THE 10TH There is no progress in this pandemic without national
and international research cooperation in phase III trials.
WEIMAR SEPSIS UPDATE OF THE This is why the major breakthroughs in treatment were
GERMAN SEPSIS SOCIETY! created by three large investigator-initiated study groups
that are unprecedented in the history of modern critical
According to the World Health Organization (WHO), care medicine: SOLIDARITY from the WHO, RECOVERY
approx. 5% of symptomatic patients with a SARS-CoV-2 from NHS England and REMAP-CAP from the EU, Canada,
infection develop a critical COVID-19 disease with Australia and the US. Furthermore, the National Institutes
respiratory failure, shock, or multiorgan dysfunction of Health (NIH) announced the Accelerating COVID-19
and 14% develop a severe disease with dyspnea, Therapeutic Interventions and Vaccines (ACTIV) public-
hypoxia, or more than 50% lung involvement on imaging. private partnership to develop a coordinated research
strategy for prioritizing and speeding development of the
This is, why we have decided to give COVID-19 most promising treatments and vaccines. These study
research a place it deserves in intensive care medicine. groups recruited ten thousands of patients in record
The COVID-19 pandemic dominates the research agenda time under the most difficult of conditions. The leading
of intensive care physicians, microbiologists, immunolo- representatives of these study groups will report on the
gists and epidemiologists worldwide. While the traditional latest results of their work in Weimar.
respiratory management of acute lung failure was in the
foreground at the beginning of the pandemic, the patho- Furthermore, results from phase II/III treatment and
physiology of COVID-19 associated ARDS is now increa- vaccination studies of the pharmaceutical industry, as
singly better understood. It became clear that beyond a well as results by diagnostic companys are expected by
systemic response there is a more compartmentalized September 2021 and will be presented. Another focus
inflammatory response in COVID-19 and adjuvant immu- of our congress will be the Surviving Sepsis Guidelines
nomodulatory strategies might improve outcome. 2021, which are about to be completed.
While prevention and vaccination strategies are Get up to date on the current state of knowledge, top
currently in the foreground of (research) political and publications from top researchers in basic and clinical
media agendas, clinical research for an evidence-based research. We plan the congress as a face-to-face event,
management of severe and critical COVID-19 disease is because that is our characteristic – get together, discuss
rather neglected. As of November 2020, 2,024 trials without limits and enjoy!
(separable into 2,895 individual treatment arms), encom-
passing total enrolment in excess of 500,000 patients had
been registered (▶ see “Trends in COVID-19 therapeutic
clinical trials”). However, ~5 % could be considered
randomized and adequately powered, and only about a
quarter of enrolled patients contributed to adequately Markus Weigand Frank M. Brunkhorst
powered and well-controlled trials. Chair GSS Secretary General GSS
4 Preface Preface 5
General information
Scientific Committee Congress venue
Prof. M. Adamzik, Bochum congress centrum neue weimarhalle
Prof. F.M. Brunkhorst, Jena UNESCO-Platz 1
Prof. A. Kaasch, Magdeburg 99423 Weimar, Germany
Prof. M. Pletz, Jena
Prof. M. Weigand, Heidelberg www.weimarhalle.de
Scientific Organisation Hauptbahnhof
Prof. F.M. Brunkhorst
Secretary general of the German Sepsis Society Schopenhauerstraße
E-mail: frank.brunkhorst@med.uni-jena.de
Ern
Carl-August-Allee
st-
er t-S tr aß e
Secretary: A. Pester
Th
älm
Phone +49 3641 9396687
an
E-mail: WeimarSepsisUpdate@med.uni-jena.de
n-S
Fr ie dr ic h- Eb
tra
ße
Congress Language
• English
Jorge-Semprùn-Platz
e
Organizer traß
de nss
Frie
weimar GmbH
e
Gesellschaft für Wirtschaftsförderung,
t- S tr a ß
Sch weimarhalle
wa
Kongress- und Tourismusservice nse
est
knech
raß
UNESCO-Platz 1 e
99423 Weimar, Germany Graben
K .- L ie b
Über
Coud
dem
raystr
aße
CME
Erfu
The meeting is certified by the rter
Stra
ße
State Medical Chamber of Thuringia
with advanced training points.
6 General Information General Information 7
Endorsements
AT A GLANCE
SCHEDULE
▶ Australian and New Zealand Intensive Care Society
Clinical Trials Group (ANZICS), Sydney
▶ Center for Sepsis Control and Care (CSCC),
Jena University Hospital
▶ Canadian Critical Care Trials Group (CCCTG),
Toronto
▶ Central and Eastern European Sepsis Forum
(SepsEast)
▶ Deutsche Gesellschaft für Internistische
Intensivmedizin und Notfallmedizin e.V. (DGIIN),
Berlin
▶ Deutsches Zentrum für Lungenforschung e.V.
(DZL), Gießen
▶ European Group on Immunology of Sepsis (EGIS),
Jena
▶ European Shock Society (ESS)
▶ Intensive Care National Audit and Research Centre
(ICNARC), and Imperial College London
▶ International Forum for Acute Care Trialists
(INFACT), Toronto
▶ Irish Critical Care Clinical Trials Network (ICCCTN),
Dublin
▶ REMAP-CAP (A Randomised, Embedded,
Multi-factorial, Adaptive Platform Trial for
Community-Acquired Pneumonia), Utrecht
▶ UK Critical Care Research Group (UKCCRG)
▶ University Medical Center Utrecht (UMCU)
8 General Information
Wednesday September 8, 2021
Time Large hall Wing hall 1 Wing hall 2 Small hall Seminar room 1 Seminar room 2
07:30 – 08:00
08:00 – 08:30
08:30 – 09:00
09:00 – 09:30 Workshop Workshop Workshop Workshop Workshop
Please follow the signs Please follow the signs Please follow the signs Please follow the signs Please follow the signs
on site on site on site on site on site
09:30 – 10:00
10:00 – 10:30
10:30 – 11:00
11:00 – 11:30
11:30 – 12:00
12:00 – 12:30
Press
12:30 – 13:00 Lunch Conference
13:00 – 13:30 Opening Session
Beyond the Pandemic 1
– Research platforms &
13:30 – 14:00
networks
14:00 – 14:30
14:30 – 15:00
15:00 – 15:30
15:30 – 16:00
16:00 – 16:30 Session 1
Beyond the pandemic 2
– COVID-19 clinical
16:30 – 17:00
registries
17:00 – 17:30
17:30 – 18:00 Session 2
Beyond the pandemic 3
18:00 – 18:30 Industrial exhibition
– COVID-19 basic
10:00 am – 5:00 pm
insights
18:30 – 19:00 The congress is generously supported by a
broad range of companies. Please visit the
from 19:00 Get-Together-Party
industrial exhibition!
Sessions Workshops Poster sessions Social Lunch symposia Press
10 Schedule at a glance Schedule at a glance 11
Thursday September 9, 2021
Wing hall 2 /
Time Large hall Wing hall 1 Small hall Seminar room 1 Seminar room 2 Eastern foyer
07:30 – 08:00
08:00 – 08:30 Session 3
Beyond the pandemic 4
– Steroids
08:30 – 09:00
09:00 – 09:30
09:30 – 10:00 Session 4
Beyond the pandemic 5
– Ventilation strategies
10:00 – 10:30
10:30 – 11:00
Session 5
11:00 – 11:30 Beyond the pandemic 6
– Immunmodulators
11:30 – 12:00 Lunch Wing hall 2
12:00 – 12:30 Lunch Symposium Lunch Symposium Lunch Symposium Lunch Symposium PS 1: Animal models
SOBI Pfizer Thermo Fisher Scientific SphingoTec / Adrenomed
Member Meeting: PS 2: Ventilation / ECMO
12:30 – 13:00
Small hall
13:00 – 13:30 PS 3: EGIS
REMAP-CAP
ITSC Meeting
13:30 – 14:00
members only
14:00 – 14:30 Session 6
Beyond the pandemic 7
– Antivirals
14:30 – 15:00
15:00 – 15:30
15:30 – 16:00 Session 7
Beyond the pandemic 8
– Anticoagulants &
16:00 – 16:30
Antibodies
16:30 – 17:00
17:00 – 17:30 Session 8
Beyond the pandemic 9
– Antiinflammation &
17:30 – 18:00
ACE-inhibiton
Member Meeting Industrial exhibition
18:00 – 18:30 8:00 am – 5:00 pm
DSG General Assembly
members only The congress is generously supported by a
18:30 – 19:00
broad range of companies. Please visit the
industrial exhibition!
Sessions Workshops Poster sessions Social Lunch symposia Press Member meetings
12 Schedule at a glance Schedule at a glance 13
Friday September 10, 2021
Time Large hall Wing hall 1 Wing hall 2 Seminar room 1 Seminar room 2 Eastern foyer
07:30 – 08:00
08:00 – 08:30 Session 9
Beyond the pandemic 10
– Long-term morbidity
08:30 – 09:00
09:00 – 09:30
09:30 – 10:00 Session 10
Sepsis 1 – evidence
from recent RCTs 1
10:00 – 10:30
10:30 – 11:00
Session 11
11:00 – 11:30 Sepsis 2 – evidence
from recent RCTs 2
11:30 – 12:00 Lunch
12:00 – 12:30 Lunch Symposium Lunch Symposium Lunch Symposium Lunch Symposium PS 4: Sepsis
CytoSorbents Inflammatix Radiometer Gilead
12:30 – 13:00
13:00 – 13:30
13:30 – 14:00
14:00 – 14:30 Hot Topic Session
14:30 – 15:00
15:00 – 15:30
15:30 – 16:00
16:00 – 16:30
16:30 – 17:00
17:00 – 17:30
17:30 – 18:00
18:00 – 18:30 Industrial exhibition
8:00 am – 3:00 pm
18:30 – 19:00 The congress is generously supported by a
broad range of companies. Please visit the
from 19:00 industrial exhibition!
Sessions Workshops Poster sessions Social Lunch symposia Press
14 Schedule at a glance Schedule at a glance 15
Wednesday
PROGRAM September 8, 2021
09:00 – 12:00 | please follow the signs on site
Workshops (parallel sessions)
09:00 – 12:00
WS1: Animal models in sepsis and COVID-19
Coordination: Osuchowski M, Vienna; Skirecki T,
Warszaw
Modeling of COVID-19: a developing success story
Osuchowski M, Vienna
Murine models of viral pneumonia – from the flu to COVID-19
Knapp S, Vienna
Tissue damage control in COVID-19: the role of parenchyma
Weis S, Jena
Modeling bacterial pneumonia: on the road to translation
Skirecki T, Warsaw
Pulmonary capillary leakage – from mice and men
David S, Zürich
Free oral presentations
Obesity contributes to severe viral pneumonia infection
course in DIO mice
Hornung F, Jena
Anserin reduces MG-induced mortality in experimental
Sepsis restoring endothelial integrity
Gallenstein N, Heidelberg
Ex vivo monocyte cytokine responses are not a proxy
for the in vivo cytokine response during experimental
human endotoxemia
Bruse N, Nijmegen
Hyperspectral Imaging for Bedside Evaluation of
Microcirculatory Tissue Oxygenation and Perfusion Quality
Dietrich M, Heidelberg
Program 17
Wednesday September 8, 2021 Wednesday September 8, 2021
Targeted rescue of synaptic plasticity improves cognitive 09:00 – 12:00
decline in sepsis-associated encephalopathy WS3: Deutsches Netzwerk Universitätsmedizin
Geis C, Jena COVID-19
09:00 – 12:00 Coordination: Boor P, Aachen; Witzenrath M, Berlin
WS2: European Group on Immunology of
NAPKON
Sepsis (EGIS)
Vehreschild J, Cologne
Coordination: Bermejo-Martin JF, Valladolid; Rubio I, Jena
COVIM
Severe COVID-19 and bacterial sepsis: variations on a theme
Klein F, Cologne
or unique disease entities?
Kox M, Nijmegen
AKTIN
Schirrmeister W, Magdeburg
Immunopathogenesis of COVID-19: lessons to learn from
special patients
DEFEAT PANDEMIcs
Cossarizza A, Modena
Boor P, Aachen
IL6: a therapeutic target in COVID-19?
CODEX
Shankar-Hari M, London
Walcher F, Magdeburg; Nauck M, Greifswald
The link between uncontrolled viral replication and host
Organo-Strat
dysregulated response in severe COVID-19
Hocke A, Berlin
Bermejo-Martin J, Salamanca
RACOON
T lymphocyte response in critically ill COVID-19 patients
Penzkofer T, Berlin
Venet F, Lyon
09:00 – 12:00
SARS-CoV-2 organ tropism and the senescence-associated WS4: Extracorporeal Life Support (ECLS) and
viral response Extracorporeal Membrane Oxygenation (ECMO)
Deinhardt-Emmer S, Jena
in sepsis- and COVID-19 associated ARDS
Coordination: Karagiannidis C, Cologne; Szułdrzyński K,
Free oral presentations
Cracow
Properties of proenkephalin in septic acute kidney injury
Nusshag C, Heidelberg
1. ECMO and COVID-19
Epidemiology of COVID-19 ECMO outcome:
Activated microglia mediate neurocognitive deficits in
regional differences
severe sepsis
Karagiannidis C, Cologne
Wickel J, Jena
Reasons for differences in outcome: Age? Resources? Money?
Broman LM, Stockholm
18 Program Program 19Wednesday September 8, 2021 Wednesday September 8, 2021
Does anticoagulation make a difference and account for • Czech Republic: Beneš J, Prague
outcome in COVID19? • Slovak Republic: Záhorec R, Bratislava
Grasselli G, Milan • Slovenia: Lainscak M, Ljubljana
• Croatia: Šustić A, Rijeka
2. ECMO and general ICU treatment
The right indication for ECMO
Weber-Carstens S, Berlin
13:00 – 15:30 | Large hall
Mechanical ventilation on vv-ECMO Opening Session
Camporota L, London Beyond the Pandemic 1 –
Research platforms & networks
Long term quality of life in ARDS and ECMO survivors
NN Chair:
Weigand M, Heidelberg; Welte T, Hannover
3. ECMO: novel techniques and development
ECMO and extracorporeal blood purification in COVID-19 Key Note Lecture
Supady A, Freiburg A.I. systems managing sepsis - hope or hype?
Gordon A, London
Lung transplantation for COVID-19-associated
Research Awards Ceremony
single organ failure?
NN German Sepsis Society Awards 2021
Weigand M, Heidelberg, Pletz M, Jena
VV ECMO versus hybrid configurations – added benefit or
SOLIDARITY – how the WHO organizes global
fancy complexity?
research on COVID-19 treatments
Szuldrzynski K, Kraków
Murthy S, Vancouver
Selected free oral presentations REMAP-CAP – a role model for global clinical
09:00 – 12:00 research in the critically ill
WS5: SepsEast – Experiences with the pandemic Webb S, Sydney
in East European countries REMAP-CAP / RECOVERY: how UK organises high-
Coordination: Beneš J, Prague; Mikaszewska-Sokolewicz quality clinical trials in the pandemic
M, Warsaw; Kluge S, Hamburg Rowan K, London
Participants: NUM – a publicy funded research network of
• Hungary: Molnár Z, Szeged German university hospitals
• Romania: Săndesc D, Timișoara Heyder R, Berlin
• Serbia: Jankovic R, Niš
• Poland: Jankowksy M, Cracow
20 Program Program 21Wednesday September 8, 2021 Wednesday September 8, 2021
15:30 – 16:00 17:40 – 19:00 | Large hall
Break Session 2
Beyond the pandemic 3 – COVID-19 basic insights
16:00 – 17:20 | Large hall Chair:
Bauer M, Jena; Briegel J, Munich
Session 1
Beyond the pandemic 2 – COVID-19 clinical registries Compartimentalized vs systemic inflammation
Shankar-Hari M, London
Chair:
Szakmany T, Cardiff; Scherag A, Jena Endothelial dysfunction
van de Veerdonk F, Nijmegen
ISARIC – a global patient registry
Merson L, London Host genetics
Kox M, Nijmegen
ICNARC – a national patient registry
Rowan K, London Pulmonary dysfunction
Welte T, Hannover
DIVI – a German ICU registry
Karagiannidis C, Cologne
Personalized medicine – phenotype anarchy or 19:00 | Weimarhalle terraces
promise realized? Get-Together-Party
Seymour CW, Pittsburgh featuring „Travelling Lights“, Berlin
17:20 – 17:40
Break
Foto: Sepsis Update 2019
Maik Schuck (c) weimar GmbH
22 Program Program 23Thursday September 9, 2021 Thursday September 9, 2021
08:00 – 09:00 | Large hall 10:45 – 11:45 | Large hall
Session 3 Session 5
Beyond the pandemic 4 – Steroids Beyond the pandemic 6 – Immunmodulators
Chair: Chair:
Gerlach H, Berlin; Adamzik M, Bochum Singer M, London; Herold S, Giessen
Current evidence from RCTs Interleukin-6 receptor antagonists - current evidence
Gordon T, London Derde L, Utrecht
Dose and treatment duration Anakinra in severe COVID-19
Myatra SN, Mumbai Marshall J, Toronto
Responders vs. non-responders suPAR-guided Anakinra treatment
Annane D, Paris Giamarellos-Bourboulis EJ, Athens
09:00 – 09:30 11:45 – 12:00
Break Break
09:30 – 10:30 | Large hall 12:00 – 13:30 | Eastern foyer
Session 4 Poster sessions
Beyond the pandemic 5 – Ventilation strategies
12:00 – 12:30
Chair: Poster session 1: Animal models
Stehr S, Leipzig; Weigand M, Heidelberg Chairs: Osuchowski M, Vienna; Skirecki T, Warsaw
Prone positioning 12:30 – 13:00
Gattinoni L, Göttingen Poster session 2: Ventilation / ECMO
Chairs: Karagiannides C, Cologne; Szułdrzyński K,
Ventilation strategies
Kraków
Nichol A, Dublin
13:00 – 13:30
ECMO
Poster session 3: EGIS
Weber-Carstens S, Berlin
Chairs: Rubio I, Jena; Bermejo-Martin J, Valladolid
10:30 – 10:45
Break
24 Program Program 25Thursday September 9, 2021 Thursday September 9, 2021
12:00 – 13:30
Lunch symposia
COVID-19 and beyond: Complex challenges for Early cytokine blockade in COVID-19 pneumonia
infection management in hospitals Large hall
Wing hall 1
Supported by Swedish Orphan Biovitrum GmbH
Supported by Pfizer Pharma GmbH Chair: Giamarellos-Bourboulis E, Athen;
Chair: Cornely O, Cologne Welte T, Hannover
Welcome Welcome
Cornely O, Cologne Giamarellos-Bourboulis E, Athen
COVID-19 complications: who gets a CAPA? Cytokine storm in COVID-19: Lessons learnt?
Cornely O, Cologne Implications for therapeutic management.
Welte T, Hannover
MRGN infections in the current context: what is new?
Hagel S, Jena Immune stratification of COVID-19 patients:
Which biomarkers can guide treatment decision?
Diagnostic stewardship: still theory or already reality? Netea M, Nijmegen
Becker S, Saarbrücken
Prevent the storm: SAVE MORE – Early IL-1 inhibition in
Panel discussion COVID-19 pneumonia.
Moderation: Cornely O, Cologne Giamarellos-Bourboulis E, Athen
Antibiotic stewardship in acute infectious disease Discussion & Summary
patients and in the follow-up Welte T, Hannover
Seminar room 1
Supported by Thermo Fisher Scientific
Moderation: Pletz M, Jena; Welte T, Hannover
Rational antibiotic therapy in oncology
von Lilienfeld-Toal M, Jena
Specifics of antibiotic stewardship in surgical patients
Eckmann C, Hann. Münden
26 Program Program 27Thursday September 9, 2021 Thursday September 9, 2021
15:30 – 16:30 | Large hall
Precision Medicine in Septic Organ Failure:
Session 7
Biomarker-guided Diagnosis and Therapy
Beyond the pandemic 8 – Anticoagulants & Antibodies
Seminar room 2
Chair:
Supported by SphingoTec GmbH / Adrenomed AG David S, Zürich; Nierhaus A, Hamburg
Chair: Weigand M, Heidelberg
Heparins – current evidence from RCT´s
Implementing new Biomarkers in Daily Practice – Zarychanski R, Winnipeg
Proenkephalin and biologically active Adrenomedullin in Sepsis
Antiplatelets
Martin L, Aachen
Bradbury C, Bristol
Biomarker-guided Approach for the Treatment of Septic Reconvalescent plasma
Shock – Precision Medicine in the AdrenOSS-2 Study Estcourt L, Oxford
Schürholz T, Aachen
16:30 – 17:00
13:30 – 14:00
Break
Break
17:00 – 18:00 | Large hall
Session 8
14:00 – 15:00 | Large hall
Beyond the pandemic 9 – Antiinflammation &
Session 6 ACE-inhibiton
Beyond the pandemic 7 – Antivirals
Chair:
Chair: Brenner T, Essen; Weis S, Jena
Kaasch A, Magdeburg; Salzberger B, Regensburg
High-dose vitamin C
Interferons Adhikari N, Toronto
Arabi Y, Riad
Simvastatin
Remdesivir McAuley D, Belfast
Pletz M, Jena
RAS-targeted therapies
Ivermectin Lawler P, Toronto
Haniffa R, Oxford
20:00 – open | Villa Haar, Ilm Park
15:00 – 15:30 Faculty Dinner
Featuring Vladimir Karparov, saxophone
Break
28 Program Program 29Friday September 10, 2021 Friday September 10, 2021
08:00 – 09:00 | Large hall 10:30 – 10:45
Session 9 Break
Beyond the pandemic 10 – Long-term morbidity
Chair: 10:45 – 11:45 | Large hall
Brunkhorst FM, Jena; Shankar-Hari M, London
Session 11
Autoantibodies Sepsis 2 – evidence from recent RCTs 2
Altmann D, London
Chair:
Secondary infections Marx G, Aachen; Oppert M, Potsdam
Russell CD, Edinburgh
Therapeutic drug monitoring for piperacillin
Long-term consequences in sepsis
Sigfrid L, Oxford Hagel S, Jena
Timing of initiation of renal replacement therapy
09:00 – 09:30 Zarbock A, Münster
Break Timing of norepinephrine initiation in patients
with septic shock
Singer M, London
09:30 – 10:30 | Large hall
Session 10
11:45 – 12:00
Sepsis 1 – evidence from recent RCTs 1
Break
Chair:
Meybohm P, Würzburg; Dembinski R, Bremen
12:00 – 13:30 | Eastern foyer
Dexmedetomidine in sepsis
Hughes CG, Nashville Poster session 4: Sepsis
Oxygenation targets for acute hypoxemic Chair:
respiratory failure Brinkmann A, Heidelberg; Hagel S, Jena
Klitgaard TL, Aalborg
Lower vs higher PEEP in patients without ARDS
Schultz MJ, Amsterdam
30 Program Program 31Friday September 10, 2021 Friday September 10, 2021
12:00 – 13:30
Lunch symposia
Hemoadsorption with CytoSorb in sepsis and “Aspergillus sepsis”: COVID-19-associated pulmonary
COVID-19 patients – an update aspergillosis (CAPA) – where do we stand?
Large hall Böll B, Cologne
Supported by CytoSorbents Europe GmbH Interaction limits satisfaction: Practical problems in the
Chair: Singer M, London; Kogelmann K, Emden use of antimycotics
Höhl R, Nürnberg
Immune system alterations and organ dysfunction in sepsis
Shankar-Hari M, London Think patient, not bug –
how reading the host response can shape the
Effects of hemoadsorption on hemodynamic stability in future of acute care medicine
septic shock Wing hall 1
Molnár Z, Budapest
Supported by Inflammatix
Multisystem inflammatory syndrome associated with Chair: Giamarellos-Bourboulis E, Athens, Uhle F,
COVID-19 – how to master the challenge? Heidelberg
Ferrer-Roca R, Barcelona
How to tame the power of systems immunology into
Use of hemoadsorption in COVID-19 patients – what did we actionable results
NN
learn so far?
Nierhaus A, Hamburg
Sensitivity, predictive values & friends – Which characteristics
Sepsis and fungal infection – a causal relationship? we should really care about in clinical practice
Seminar room 2 Gerlach H, Berlin
Prospective evaluation of host-response diagnostics in ED –
Supported by Gilead Sciences GmbH
the Berlin experience
Chair: Weigand M, Heidelberg
Bauer W, Berlin
Sepsis as a risk factor for mycosis?
Host-response based endotyping and prognostication of
Wichmann D, Hamburg
patients with COVID19 – the Greek experience
Giamarellos-Bourboulis E, Athens
Candida sepsis – new trends?
Richter D, Heidelberg
32 Program Program 33Friday September 10, 2021
Biomarker, Guidelines, and future trends within
Sepsis and COVID-19
Seminar room 1
Supported by Radiometer GmbH
Chair: Oppert M, Potsdam
Guideline development and future trends within sepsis
treatment
Singer M, London
Biomarkers: what matters if the result has to be ready fast
Petersmann A, Oldenburg
Biomarker for antibiotic stewardship in sepsis and COVID-19
Oppert M, Potsdam
13:30 – 14:00
Break
14:00 – 15:00 | Large hall
Hot Topic Session
Imagine a world safer
Chair:
Weigand M, Heidelberg; Adamzik M, Bochum
Biomarkers for antimicrobial stewardship in
COVID-19 times
from infection. We do.
Kox M, Nijmegen
Crystalloid composition and fluid bolus in
critically ill patients - results of the BaSICS trial
Weigand M, Heidelberg
Double trouble: a pandemic of
obesity and COVID-19
Scherag, A, Jena
34 Program Program 35Speakers and chairs
CHAIRS
SPEAKERS & Michael Adamzik
Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie,
Universitätsklinikum Knappschaftskrankenhaus Bochum,
Bochum, Germany
Marylyn Addo
I. Medizinische Klinik und Poliklinik, Universitätsklinikum
Hamburg-Eppendorf, Hamburg, Germany
Neill Adhikari
Sunnybrook Health Sciences Centre, University of Toronto,
Toronto, Canada
Danny Altmann
Department of Immunology and Inflammation Imperial College
London, London, United Kingdom
Djillali Annane
Réanimation médicale adulte, Hôpital Raymond-Poincaré,
Paris, France
Yaseen Arabi
Intensive Care Department, King Abdullah International Medical
Research Center, Riyadh, Saudi Arabia
Wolfgang Bauer
Zentrale Notaufnahme, Charité - Universitätsmedizin Berlin,
Berlin, Germany
Michael Bauer
Klinik für Anästhesiologie und Intensivmedizin,
Universitätsklinikum Jena, Jena, Germany
Sören Becker
Institut für Medizinische Mikrobiologie und Hygiene,
Universität des Saarlandes, Saarbrücken, Germany
Jan Beneš
Department of Anesthesiology and Intensive Care Medicine,
Charles University in Prague | CUNI, Plzeň-Lochotín,
Czech Republic
Jesus F. Bermejo-Martin
Group for Biomedical Research in Sepsis, Hospital Clínico
Universitario de Valladolid/IECSCYL, Valladolid, Spain
Speakers & chairs 37Boris Böll Stefanie Deinhardt-Emmer
Innere Medizin I, Uniklinik Köln, Cologne, Germany Institut für Medizinische Mikrobiologie, Universitätsklinikum Jena,
Jena, Germany
Peter Boor Rolf Dembinski
Institut für Pathologie, Universitätsklinikum Aachen, Klinik für Intensivmedizin und Notfallmedizin, Klinikum Bremen
Aachen, Germany Mitte, Bremen, Germany
Charlotte A. Bradbury Lennie Derde
Weston NHS Foundation Trust, University Hospitals Bristol, Intensive Care Medicine, UMC Utrecht, Utrecht, Netherlands
Bristol, United Kingdom
Christian Eckmann
Thorsten Brenner Allgemein-, Viszeral- und Thoraxchirurgie, Klinikum Hann. Münden,
Klinik für Anästhesiologie und Intensivmedizin, Hann. Münden, Germany
Universitätsklinikum Essen, Essen, Germany
Lise Estcourt
Josef Briegel Clinical Trials Unit, NHS Blood and Transplant, Oxford,
Klinik für Anästhesiologie, Klinikum der Universität München, United Kingdom
Munich, Germany
Ricard Ferrer Roca
Alexander Brinkmann Intensive Care Medicine, Vall d’Hebron General Hospital,
Klinik für Anästhesie, operative Intensivmedizin und spezielle Barcelona, Spain
Schmerztherapie, Klinikum Heidenheim , Heidenheim, Germany
Luciano Gattinoni
Lars Mikael Broman Department of Anesthesiology, Emergency and Intensive Care
Department of Physiology and Pharmacology, Karolinska University Medicine, University of Göttingen, Göttingen, Germany
Hospital, Stockholm, Sweden
Herwig Gerlach
Frank M. Brunkhorst Klinik für Anästhesie, operative Intensivmedizin und Schmerz-
Zentrum für Klinische Studien, Universitätsklinikum Jena, therapie, Vivantes Klinikum Neukölln, Berlin, Germany
Jena, Germany
Evangelos J. Giamarellos-Bourboulis
Luigi Camporota 4th Department of Medicine, ATTIKON University Hospital Athens,
Critical Care Medicine, Guy‘s and St Thomas‘ NHS Foundation Trust, Athens, Greece
London, United Kingdom
Anthony Gordon
Oliver Cornely Anaesthetics, Pain Medicine and Intensive Care, Imperial College
Studienzentrum Infektiologie, Uniklinik Köln, Köln, Germany London, London, United Kingdom
Andrea Cossarizza Giacomo Grasselli
Dipartimento di Scienze Mediche e Chirurgiche materno infantili Department of Pathophysiology and Transplantation,
e dell‘adulto, Università degli Studi di Modena e Reggio Emilia, Università degli Studi di Milano, Milan, Italy
Modena, Italy
Stefan Hagel
Sascha David Institut für Infektionsmedizin und Krankenhaushygiene,
Institut für Intensivmedizin, Universitätsspital Zürich, Universitätsklinikum Jena, Jena, Germany
Zürich, Switzerland
38 Speakers & chairs Speakers & chairs 39Rashan Haniffa Stefan Kluge
Anaesthetics Department, University College London, London, Klinik für Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf,
United Kingdom Hamburg, Germany
Susanne Herold Sylvia Knapp
Medizinische Klinik II, SP Infektiologie, Universitätsklinikum Gießen, Laboratory of Infection Biology, Medical University Vienna,
Gießen, Germany Vienna, Austria
Ralf Heyder Klaus Kogelmann
Stabsstelle Externe Vernetzung und Strategische Kooperationen, Klinik für Anästhesiologie und Intensivmedizin, Klinikum Emden,
Charité - Universitätsmedizin Berlin, Berlin, Germany Emden, Germany
Andreas Hocke Matthijs Kox
Med. Klinik m.S. Infektiologie und Pneumologie, Molekulare Intensive Care Medicine, Radboud University Medical Centre,
Bildgebung, Charité - Universitätsmedizin Berlin, Berlin, Germany Nijmegen, Netherlands
Rainer Höhl Mitja Lainscak
Institut für Klinikhygiene, Medizinische Mikrobiologie und Klinische Medicinska fakulteta, Univerza v Ljubljani, Ljubljana, Slovenia
Infektiologie, Klinikum Nürnberg Nord, Nuremberg, Germany
Patrick Lawler
Christopher Hughes Institute of Medical Science, University of Toronto, Toronto, Canada
Department of Anesthesiology, Vanderbilt University Medical
Center, Nashville, USA John Marshall
Department of Surgery, University of Toronto, Toronto, Canada
Radmilo J. Jankovic
Anesthesiology and Reanimation Center, Clinical Center Niš, Lukas Martin
Niš, Serbia Klinik für Operative Intensivmedizin und Intermediate Care,
Universitätsklinikum Aachen, Aachen, Germany
Miłosz Jankowski
Internal Medicine, Jagiellonian University Kraków, Kraków, Poland Gernot Marx
Klinik für Operative Intensivmedizin und Intermediate Care,
Achim Kaasch Universitätsklinikum Aachen, Aachen, Germany
Institut für Medizinische Mikrobiologie und Krankenhaushygiene,
Universitätsmedizin Magdeburg, Magdeburg, Germany Danny McAuley
Dentistry and Biomedical Sciences, Queen‘s University School of
Christian Karagiannidis Medicine, Belfast, United Kingdom
Lungenklinik, Krankenhaus Köln-Merheim, Cologne, Germany
Laura Merson
Florian Klein The Centre for Tropical Medicine and Global Health,
Institut für Virologie, Uniklinik Köln, Cologne, Germany University of Oxford, Oxford, United Kingdom
Thomas Lass Klitgaard Patrick Meybohm
Department of Clinical Medicine, Aalborg University Hospital, Klinik und Poliklinik für Anästhesiologie, Intensivmedizin,
Aalborg, Denmark Notfallmedizin und Schmerztherapie, Universitätsklinikum
Würzburg, Würzburg, Germany
40 Speakers & chairs Speakers & chairs 41Malgorzata Mikaszewska-Sokolewicz Kathy Rowan
Department of Anesthesiology and Intensive Care, Chief Investigator, ICNARC, London, United Kingdom
Medical University of Warsaw, Warsaw, Poland
Ignacio Rubio
Zsolt Molnár FZL - FB Experimentelle Anästhesie, Universitätsklinikum Jena,
Department of Anesthesiology and Intensive Care, Jena, Germany
University of Szeged, Faculty of Medicine, Szeged, Hungary
Clark D Russell
Srinivas Murthy Infection Medicine, The University of Edinburgh,
Department of Pediatrics, University of British Columbia, Edinburgh, United Kingdom
Vancouver, Canada
Dorel Sandesc
Sheila N. Myatra Anestezie, Brol Medical Center, Timisora, Romania
Department of Anesthesiology, Critical Care and Pain,
Tata Memorial Hospital, Mumbai, India André Scherag
Institut für Medizinische Statistik, Informatik und Datenwissen-
Alistair Nichol schaften, Universitätsklinikum Jena, Jena, Germany
Critical Care Medicine, University College Dublin, Dublin, Ireland
Wiebke Schirrmeister
Axel Nierhaus Universitätsklinik für Unfallchirurgie, Otto-von-Guericke-Universität
Klinik für Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf, Magdeburg, Magdeburg
Hamburg, Germany
Marcus J. Schultz
Michael Oppert Intensive Care Medicine, Amsterdam University Medical Centers,
Klinik für Notfall- und Internistische Intensivmedizin, Amsterdam, Netherlands
Klinikum Ernst von Bergmann, Potsdam, Germany
Christopher W. Seymour
Marcin Osuchowski Department of Critical Care Medicine, University of Pittsburgh,
Experimentelle und Klinische Traumatologie, Pittsburgh, USA
Ludwig-Boltzmann-Institut, Wien, Austria
Manu Shankar-Hari
Tobias Penzkofer Department of Critical Care Medicine, King‘s College London,
Klinik für Radiologie, Charité - Universitätsmedizin Berlin, London, United Kingdom
Berlin, Germany
Louise Sigfrid
Astrid Petersmann Centre for Tropical Medicine and Global Health,
Institut für Klinische Chemie und Laboratoriumsmedizin, University of Oxford, Oxford, United Kingdom
Klinikum Oldenburg, Oldenburg, Germany
Mervyn Singer
Mathias Pletz Bloomsbury Institute for Intensive Care Medicine,
Institut für Infektionsmedizin und Krankenhaushygiene, University College Hospital, London, United Kingdom
Universitätsklinikum Jena, Jena, Germany
Tomasz Skirecki
Daniel Richter Department of Anesthesiology and Intensive Care,
Klinik für Anästhesiologie, Universitätsklinikum Heidelberg, Centre of Postgraduate Medical Education, Warsaw, Poland
Heidelberg, Germany
42 Speakers & chairs Speakers & chairs 43Sebastian Stehr Markus Weigand
Klinik und Poliklinik für Anästhesiologie und Intensivtherapie, Anästhesiologische Klinik, Universitätsklinikum Heidelberg,
Universitätsklinikum Leipzig, Leipzig, Germany Heidelberg, Germany
Alexander Supady Sebastian Weis
Klinik für Kardiologie und Angiologie, Universitätsklinikum Freiburg, Institut für Infektionsmedizin und Krankenhaushygiene,
Herzzentrum, Freiburg, Germany Universitätsklinikum Jena, Jena, Germany
Alan Šustić Tobias Welte
Department of Anesthesiology, Resuscitation and Intensive Care, Klinik für Pneumologie, Medizinische Hochschule Hannover,
University of Rijeka, Rijeka, Croatia Hannover, Germany
Tamás Szakmany Dominic Wichmann
Cardiff University School of Medicine, Director of Critical Illness Klinik für Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf,
Research, Cardiff, United Kingdom Hamburg, Germany
Konstanty Szułdrzyński Martin Witzenrath
Klinika Alergii i Immunologii, Uniwersytet Jagielloński Collegium Medizinische Klinik m. S. Infektiologie und Pneumologie,
Medicum, Kraków, Poland Charité – Universitätsmedizin Berlin, Berlin, Germany
Florian Uhle Roman Záhorec
Institut für Immunologie, Universitätsklinikum Heidelberg, Department of Anesthesiology and Intensive Medicine,
Heidelberg, Germany Comenius University Bratislava, Bratislava, Slovakia
Frank van de Veerdonk Alexander Zarbock
Center for Infectious Diseases, Radboud University Medical Center, Klinik für Anästhesiologie, operative Intensivmedizin und Schmerz-
Nijmegen, Netherlands therapie, Universitätsklinikum Münster, Münster, Germany
Janne Vehreschild Ryan Zarychanski
Innere Medizin I, Uniklinik Köln, Cologne, Germany Department of Medicine and Department of Community Health
Sciences, University of Manitoba, Winnipeg, Canada
Fabienne Venet
Immunology Laboratory, Hôpital E. Herriot - Hospices Civils de Lyon,
Lyon, France
Marie von Lilienfeld-Toal
Hämatologie und Internistische Onkologie,
Universitätsklinikum Jena, Jena, Germany
Steve Webb
School of Epidemiology and Preventive Medicine,
Monash University, Melbourne, Australia
Steffen Weber-Carstens
Klinik für Anästhesiologie mit Schwerpunkt operative
Intensivmedizin, Charité – Universitätsmedizin Berlin, Berlin, Germany
44 Speakers & chairs Speakers & chairs 45Lunch symposia
EXHIBITORS
COMPANIES & ▶ CytoSorbents Europe GmbH // 17.000€
▶ Swedish Orphan Biovitrum GmbH // 17.000€
▶ Adrenomed AG & SphingoTec GmbH // 16.400€
▶ Gilead Sciences GmbH // 15.000€
▶ Inflammatix // 15.000€
▶ Pfizer Pharma GmbH // 15.000€
▶ Radiometer GmbH // 15.000€
▶ Thermo Fisher Scientific // 15.000€
Companies & exhibitors 47Exhibitors
▶ bioMérieux Deutschland GmbH // 4.800€
▶ Becton Dickinson GmbH // 3.050€ SICHERE
▶ Biotest AG // 2.400€
SEPSISDIAGNOSE
▶ Biocartis N.V. // 2.400€
IN NUR EINER
▶ Pascoe pharmazeutische Präparate GmbH // 2.300€
▶ CSL Behring GmbH // 1.800€
STUNDE
▶ ExThera Medical Europe B.V. // 1.800€
▶ FUJIFILM Wako Chemicals Europe GmbH // 1.800€
Ein Schnelltest auf Basis der
▶ Fresenius Medical Care GmbH // 1.800€ Patientenimmunreaktion
▶ InfectoPharm Arzneimittel GmbH // 1.800€ Differenzierung zwischen Sepsis
▶ MSD Sharp & Dohme GmbH // 1.800€
und SIRS*
▶ Shionogi GmbH // 1.800€ Zuverlässige Ergebnisse in 1 Stunde
Vollautomatischer Prozess von der
Probe bis zum Ergebnis
Ergebnis als Wahrscheinlichkeits-
Risiko-Wert (SeptiScore®)
Weitere informationen zu Idylla™?
www.biocartis.com oder
info@biocartis.com
*SIRS (systemische inflammatorisches Response-Syndrom), auch INSI (Infection Negative Systemic Inflammation)
SeptiCyte® RAPID ist in der EU mit der CE-Kennzeichnung für IVD zertifiziert. Immunexpress verwendet
die Marke Idylla unter Lizenz von Biocartis. Der SeptiCyte® RAPID Test verwendet SuperScript™ III
Reverse Transcriptase. Die Marke SuperScript III ist Eigentum der Life Technologies Corporation.
Die Verfügbarkeit auf dem Markt variiert und sollte über immunexpress.com geprüft werden.
48 Companies & exhibitors Companies & exhibitors 49Site map Registration Exhibitors Catering
4 6 8 9
5 7
3 Eastern foyer | Poster sessions
1
2 12 14
Transition seminar building
13 15
Main entrance
Small
Large hall 16
hall
17
20
32 21 18
33 19
31 30 29 26 23 22
28 27 25 24
34
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49
Faculty lounge DSG lounge
Wing hall 1 Terraces Terraces Wing hall 2
Park Park
50 Companies & exhibitors Companies & exhibitors 51Exhibitors & further sponsors Listed by booth number In alphabetical order 13 Radiometer GmbH 41 Becton Dickinson GmbH 14 Pascoe pharmazeutische Präparate GmbH 15 Biocartis N.V. 15 Biocartis N.V. 17 bioMérieux Deutschland GmbH 17 bioMérieux Deutschland GmbH 42 Biotest AG 18 Fresenius Medical Care GmbH 39 Center for Sepsis Control and Care (CSCC) 19 FUJIFILM Wako Chemicals Europe GmbH 43 CSL Behring GmbH 20 Gilead Sciences GmbH 26 Cytosorbents 24 InfectoPharm Arzneimittel GmbH 28 ExThera Medical Europe B.V. 25 Shionogi GmbH 18 Fresenius Medical Care GmbH 26 Cytosorbents 19 FUJIFILM Wako Chemicals Europe GmbH 28 ExThera Medical Europe B.V. 20 Gilead Sciences GmbH 29 SphingoTec GmbH / Adrenomed AG 37 Infectognostics 30 Inflammatix 24 InfectoPharm Arzneimittel GmbH 31 Swedish Orphan Biovitrum GmbH 30 Inflammatix 35 Sepsis-Stiftung 45 MSD Sharp & Dohme GmbH 37 Infectognostics 14 Pascoe pharmazeutische Präparate GmbH 39 Center for Sepsis Control and Care (CSCC) 13 Radiometer GmbH 41 Becton Dickinson GmbH 35 Sepsis-Stiftung 42 Biotest AG 25 Shionogi GmbH 43 CSL Behring GmbH 29 SphingoTec GmbH / Adrenomed AG 45 MSD Sharp & Dohme GmbH 31 Swedish Orphan Biovitrum GmbH 52 Companies & exhibitors Companies & exhibitors 53
Foto: Sepsis Update 2019, Maik Schuck (c) weimar GmbH Contact Deutsche Sepsis-Gesellschaft e.V. Am Klinikum 1 07747 Jena, Germany ▶ www.sepsis-gesellschaft.de ▶ weimarsepsisupdate@med.uni-jena.de Tel.: +49 3641 939 66 87
LUNCH
SYMPOSIUM
Precision Medicine in Septic Organ Failure:
Biomarker-guided Diagnosis and Therapy
Thursday 09.09.2021 I 12:00-1:30 p.m. CEST
Chair: Prof. Dr. med. Markus Weigand
Universitätsklinikum Heidelberg
Implementing new Biomarkers in Daily Practice
- Proenkephalin and biologically active Adrenomedullin in Sepsis
Priv.- Doz. Dr. med. Lukas Martin,
Universitätsklinikum RWTH Aachen
Biomarker-guided Approach for the Treatment of Septic Shock
- Precision Medicine in the AdrenOSS-2 Study
Prof. Dr. med. Tobias Schürholz,
Universitätsklinikum RWTH Aachen Visit us
at
BOOTH
29
www.sphingotec.com www.adrenomed.comYou can also read
